Some breakthrough results of important clinical trials by Sanofi-Aventis Ltd. Were presented in the conference showing significant survival benefit for cancer patients, says a press release.

The study involved the drugs named Eloxatin (Oxaliplatin), Taxotere (Docetaxel), Aflibercept (VEGF-Trap), S-1 (Oral Fluoropyrimidine) and Trovax (therapeutic cancer vaccine) which showed significant advances in the field of cancer treatment.